Rhumbline Advisers boosted its stake in Petmed Express Inc (NASDAQ:PETS) by 9.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 60,315 shares of the company’s stock after purchasing an additional 5,240 shares during the quarter. Rhumbline Advisers owned about 0.29% of Petmed Express worth $2,744,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently added to or reduced their stakes in the stock. Arizona State Retirement System grew its holdings in Petmed Express by 224.7% in the fourth quarter. Arizona State Retirement System now owns 34,631 shares of the company’s stock valued at $1,576,000 after purchasing an additional 23,964 shares during the period. Capital Fund Management S.A. purchased a new stake in Petmed Express in the fourth quarter valued at approximately $473,000. Pinebridge Investments L.P. grew its holdings in Petmed Express by 259.7% in the fourth quarter. Pinebridge Investments L.P. now owns 9,197 shares of the company’s stock valued at $419,000 after purchasing an additional 6,640 shares during the period. Wells Fargo & Company MN grew its holdings in Petmed Express by 1.4% in the fourth quarter. Wells Fargo & Company MN now owns 144,494 shares of the company’s stock valued at $6,574,000 after purchasing an additional 2,039 shares during the period. Finally, First Trust Advisors LP purchased a new stake in Petmed Express in the fourth quarter valued at approximately $2,677,000. Hedge funds and other institutional investors own 91.30% of the company’s stock.
Shares of Petmed Express Inc (NASDAQ PETS) opened at $43.27 on Friday. Petmed Express Inc has a 52 week low of $19.80 and a 52 week high of $57.80. The stock has a market cap of $891.41, a P/E ratio of 25.60, a price-to-earnings-growth ratio of 2.44 and a beta of 0.93.
Petmed Express (NASDAQ:PETS) last released its quarterly earnings data on Monday, January 22nd. The company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.11. Petmed Express had a net margin of 12.84% and a return on equity of 34.04%. The company had revenue of $60.10 million during the quarter, compared to the consensus estimate of $56.76 million. During the same period in the previous year, the firm earned $0.24 earnings per share. Petmed Express’s revenue for the quarter was up 13.6% on a year-over-year basis. analysts expect that Petmed Express Inc will post 1.77 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, February 16th. Shareholders of record on Monday, February 5th were paid a dividend of $0.25 per share. This is an increase from Petmed Express’s previous quarterly dividend of $0.20. This represents a $1.00 annualized dividend and a yield of 2.31%. The ex-dividend date was Friday, February 2nd. Petmed Express’s payout ratio is currently 59.17%.
In other Petmed Express news, CEO Menderes Akdag sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, January 11th. The shares were sold at an average price of $51.00, for a total transaction of $1,530,000.00. Following the completion of the sale, the chief executive officer now directly owns 490,000 shares in the company, valued at $24,990,000. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Ronald J. Korn sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $48.38, for a total transaction of $241,900.00. Following the sale, the director now owns 68,833 shares of the company’s stock, valued at $3,330,140.54. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 45,000 shares of company stock valued at $2,341,900. 4.00% of the stock is owned by insiders.
A number of equities research analysts recently issued reports on PETS shares. ValuEngine upgraded shares of Petmed Express from a “hold” rating to a “buy” rating in a report on Wednesday, February 7th. BidaskClub downgraded shares of Petmed Express from a “strong-buy” rating to a “buy” rating in a report on Friday, January 19th. Finally, Northcoast Research set a $58.00 target price on shares of Petmed Express and gave the company a “buy” rating in a report on Wednesday, January 3rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $42.80.
TRADEMARK VIOLATION NOTICE: This article was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://ledgergazette.com/2018/03/18/petmed-express-inc-pets-position-raised-by-rhumbline-advisers.html.
Petmed Express Company Profile
PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.
Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.